Results 271 to 280 of about 1,703,637 (357)

Exploring the Anti‐Diabetic Potential of Anthocyanins: From Biochemical Pathways to Human Trials

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Diabetes mellitus (DM) is a global health challenge with increasing prevalence rates, particularly in low‐ and middle‐income countries. Anthocyanins (ACs) are potential bioactive compounds found in various fruits and vegetables, attracting the attention of researchers due to their possible role in managing diabetes and its complications ...
Lakshay Panchal, Sangeeta Yadav, Akash Kumar, Tanbeer Kaur, Yashna Bawa, Sarvesh Rustagi, Rahul Mehra   +6 more
wiley   +1 more source

Interactive effects of high-density lipoprotein cholesterol and insulin resistance on depression: results from the NHANES (2005-2018). [PDF]

Lipids Health Dis
Rao L, Li J, Xian X, Hu Y, Xian Y.
europepmc   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in relation to benign prostatic hyperplasia: A cross-sectional study. [PDF]

Medicine (Baltimore)
Lu Z, Wan H, Liu W, Zhao J, Guo M.
europepmc   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and the risk of insulin resistance: results from the NHANES 2003-2016. [PDF]

BMC Endocr Disord
Li B, Zha Y, Deng M, Niu L, Li X, Zhu R, Tian J, Jing L.   +7 more
europepmc   +1 more source

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

Clinical Pharmacology &Therapeutics, EarlyView.
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal.
Hotaka Maruyama, Eiko Iwasa, Shinya Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama, Taihei Tanaka   +5 more
wiley   +1 more source

Evaluation of systemic inflammatory biomarkers associated with high-density lipoprotein in keratoconus patients: a retrospective case-control study. [PDF]

BMC Ophthalmol
Çakır B, Osmanoğlu MM, Sönmezoğlu BG.   +2 more
europepmc   +1 more source

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Clinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park, Jae‐Hwan Lee, Jin‐Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong‐Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin‐Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung‐Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo‐Soo Kim, Moo Hyun Kim, Do‐Sun Lim, Eun‐Seok Shin, Paul A. Gurbel, Young‐Hoon Jeong, on behalf of the PTRG‐DES Consortium Investigators   +22 more
wiley   +1 more source

Relation of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio to residual risk in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF Project III cohort. [PDF]

Cardiovasc Diabetol
Soler-Espejo E, Chen Y, Rivera-Caravaca JM, Ramos-Bratos MP, Esteve-Pastor MA, Marín F, Roldán V, Lip GYH.   +7 more
europepmc   +1 more source